Arla Foods Ingredients launches dry blend protein rich in alpha-lactalbumin for infant formula

March 11, 2021
Sebastian Krawiec

Arla Foods Ingredients launched a new dry-blend protein ingredient designed to help infant formula manufacturers reduce production costs without compromising on safety and quality.

Arla Foods Ingredients (Viby J, Denmark) launched a new dry-blend protein ingredient designed to help infant formula manufacturers reduce production costs without compromising on safety and quality. The blend, called Lacprodan Premium Alpha-10 is rich in alpha-lactalbumin, the most abundant whey protein in human milk, and essential amino acids. This is Arla Foods Ingredients' first ingredient designed for dry blending, a process that help reduce energy usage and product costs for manufacturers and offers greater flexibility to produce more recipes from one base powder.

Produced to the highest safety standards, Lacprodan Premium Alpha-10 is free from Cronobacter sakazakii, a bacterium that can cause serious infections in infants, and compliant with new Chinese food safety standards, making it ideal for products entering the world’s largest formula market. According to Arla Foods Ingredients, using alpha-lactalbumin can result in a closer match with the protein composition of human milk, promote gut comfort and healthy growth, and enhance protection from intestinal infections.

“We’ve been offering dry blend lactose for many years. Until now, dry-blendable proteins have been less common, so we’re excited to launch Lacprodan Premium ALPHA-10, which is a win-win solution for formula manufacturers,” said Lone Strøm, head of sales development, pediatrics, at Arla Foods Ingredients, in a press release. “It combines the clinically proven benefits of alpha-lactalbumin with the opportunity to reduce energy usage and production costs. Most importantly it comes with a commitment to quality and safety – which are paramount in the infant nutrition sector – from a trusted, reliable partner.”

Lacprodan Premium Alpha-10 is currently available globally in trial quantities. Commercial quantities will be available in the second half of 2021.